Influence of atorvastatin calcium tablets on small and dense low-density lipoprotein cholesterol in myocardial infarction patients

doi:10.3969/j.issn.1673-8640.2019.03.05

Abstract

Abstract:

Objective To investigate the change of small and dense low-density lipoprotein cholesterol （sd-LDL-C） in myocardial infarction patients and the level change of sd-LDL-C after taking atorvastatin calcium tablets. Methods The levels of total cholesterol （TC）,triglyceride （TG）,high-density lipoprotein cholesterol （HDL-C）,low-density lipoprotein cholesterol （LDL-C） and sd-LDL-C in 96 patients with myocardial infarction before treatment and after treatment with atorvastatin calcium tablets orally for 4 weeks and 50 healthy subjects （healthy control group） were determined. Coronary computed tomography （CT） was used to determine the degree of coronary stenosis. The patients with myocardial infarction were classified into 3 groups according to the coronary CT results （<50%,50%-70% and >70%）. Results Compared to healthy control group,blood pressure,TG,LDL-C,sd-LDL-C and sd-LDL-C/LDL-C ratio in myocardial infarction group were increased （P<0.05）,and HDL-C was decreased （P<0.05）. There was no statistical significance for TC between the 2 groups （P>0.05）. TC,sd-LDL-C and sd-LDL-C/LDL-C ratios were increased in turn in coronary stenosis <50%,50%-70% and >70% groups （P<0.05,P<0.01）,and other indicators had no statistical significance （P>0.05）. Logistic regression analysis showed that TC,sd-LDL-C and sd-LDL-C/LDL-C ratio were risk factors for coronary stenosis>70% [odds ratios （OR） were 2.680,2.000 and 7.819,95% confidence intervals （CI） were 1.780-7.030,1.103-3.681 and 1.430-40.263]. In coronary stenosis>70% group,sd-LDL-C and sd-LDL-C/LDL-C ratio after treatment were lower than those before treatment （P<0.05）,and there was no statistical significance for coronary stenosis <50% and 50%-70% groups （P>0.05）. Conclusions Sd-LDL-C and sd-LDL-C/LDL-C ratio can be used as risk factors for myocardial infarction. The atorvastatin calcium tablets can decrease sd-LDL-C and sd-LDL-C-c/LDL-C ratio effectively.

Key words: Small and dense low-density lipoprotein, Myocardial infarction tablet, Atorvastatin calcium, Coronary artery stenosis

CLC Number:

R446.1

PAN Yue, HE Yong, JIN Jing, WANG Rongqi. Influence of atorvastatin calcium tablets on small and dense low-density lipoprotein cholesterol in myocardial infarction patients[J]. Laboratory Medicine, 2019, 34(3): 211-214.

Figures/Tables 3

References 8

[1]	ALI M,MADJID M.Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target[J]. Future Cardiol,2009,5(2):159-173.
[2]	SHARMA S B,GARG S.Small dense LDL: risk factor for coronary artery disease (CAD) and its therapeutic modulation[J]. Indian J Biochem Biophys,2012,49(2):77-85.
[3]	国家卫生计生委合理用药专家委员会,中国药师协会. 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南[J]. 中国医学前沿杂志(电子版),2016,8(8):25-41.
[4]	张小刚. 低密度脂蛋白颗粒大小及sd-LDL浓度比与冠脉病变程度的相关性研究[D]. 太原:山西医科大学,2014.
[5]	OTVOS J D,COLLINS D,FREEDMAN D S,et al.Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial[J]. Circulation,2006,113(12):1556-1563.
[6]	AI M,OTOKOZAWA S,ASZTALOS B F,et al.Small dense LDL cholesterol and coronary heart disease:results from the Framingham offspring study[J]. Clin Chem,2010,56(6):967-976.
[7]	ALLAIRE J,VORS C,COUTURE P,et al.LDL partical number and size and cardiovascular risk:anything new under the sun?[J]. Curr Opin Lipidol,2017,28(3):261-266.
[8]	GOEL P K,ASHFAQ F,KHANNA R,et al.The association between small dense low density lipoprotein and coronary artery disease in North Indian patients[J]. Indian J Clin Biochem,2017,32(2):186-192.

组别	例数	BMI（kg/m²）	吸烟史[例（%）]	收缩压（kPa）	舒张压（kPa）	血糖（mmol/L）
心肌梗死组	96	23.9±5.8	47（49.0）	19.5±1.2	13.6±1.0	6.1±1.6
正常对照组	50	23.1±6.7	33（34.3）	16.4±1.4	11.7±0.7	5.8±1.2
统计值		0.749		13.971	13.363	1.274
P值		0.455		<0.01	<0.01	0.205
组别	TC （mmol/L）	TG （mmol/L）	HDL-C （mmol/L）	LDL-C （mmol/L）	sd-LDL-C（mmol/L）	sd-LDL-C/LDL-C比值
心肌梗死组	4.84±0.99	1.80±0.31	1.12±0.23	2.99±0.82	1.19±0.21	0.39±0.19
正常对照组	4.82±1.05	1.46±0.25	1.28±0.34	2.65±0.83	1.01±0.53	0.34±0.11
统计值	0.113	7.166	2.99	2.368	2.309	2.011
P值	0.91	<0.01	0.004	0.019	0.025	0.046

组别	例数	BMI（kg/m²）	吸烟史[例（%）]	收缩压（kPa）	舒张压（kPa）	血糖（mmol/L）
心肌梗死组	96	23.9±5.8	47（49.0）	19.5±1.2	13.6±1.0	6.1±1.6
正常对照组	50	23.1±6.7	33（34.3）	16.4±1.4	11.7±0.7	5.8±1.2
统计值		0.749		13.971	13.363	1.274
P值		0.455		<0.01	<0.01	0.205
组别	TC （mmol/L）	TG （mmol/L）	HDL-C （mmol/L）	LDL-C （mmol/L）	sd-LDL-C（mmol/L）	sd-LDL-C/LDL-C比值
心肌梗死组	4.84±0.99	1.80±0.31	1.12±0.23	2.99±0.82	1.19±0.21	0.39±0.19
正常对照组	4.82±1.05	1.46±0.25	1.28±0.34	2.65±0.83	1.01±0.53	0.34±0.11
统计值	0.113	7.166	2.99	2.368	2.309	2.011
P值	0.91	<0.01	0.004	0.019	0.025	0.046

组别	例数	TC （mmol/L）	TG （mmol/L）	HDL-C （mmol/L）	LDL-C （mmol/L）	sd-LDL-C （mmol/L）	sd-LDL-C/ LDL-C比值
狭窄<50%组	37	4.70±0.97	1.55±0.37	1.22±0.31	3.09±0.78	0.98±0.47	0.33±0.14
狭窄50%~70%组	30	4.89±0.71	1.93±0.46	1.14±0.26	2.82±0.64	1.13±0.54	0.37±0.11
狭窄>70%组	29	5.11±0.63^*	1.82±0.39	1.03±0.42	3.04±0.95	1.26±0.29^*	0.42±0.27^**
F值		3.318	2.677	2.636	1.031	3.196	7.426
P值		<0.05	>0.05	>0.05	>0.05	<0.05	<0.01

组别	例数	TC （mmol/L）	TG （mmol/L）	HDL-C （mmol/L）	LDL-C （mmol/L）	sd-LDL-C （mmol/L）	sd-LDL-C/ LDL-C比值
狭窄<50%组	37	4.70±0.97	1.55±0.37	1.22±0.31	3.09±0.78	0.98±0.47	0.33±0.14
狭窄50%~70%组	30	4.89±0.71	1.93±0.46	1.14±0.26	2.82±0.64	1.13±0.54	0.37±0.11
狭窄>70%组	29	5.11±0.63^*	1.82±0.39	1.03±0.42	3.04±0.95	1.26±0.29^*	0.42±0.27^**
F值		3.318	2.677	2.636	1.031	3.196	7.426
P值		<0.05	>0.05	>0.05	>0.05	<0.05	<0.01

组别	例数	sd-LDL-C （mmol/L）	sd-LDL-C/ LDL-C比值
狭窄<50%组	37
治疗前		0.98±0.47	0.33±0.14
治疗4周后		0.99±0.31	0.33±0.21
狭窄50%~70%组	30
治疗前		1.13±0.54	0.37±0.11
治疗4周后		1.12±0.67	0.36±0.23
狭窄>70%组	29
治疗前		1.26±0.29	0.42±0.27
治疗4周后		1.11±0.34^#	0.37±0.10^##